Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenichi Suda

Showing results (11-20 of 127) with videos related to

Pageof 13
Sort By:
Nihon Geka Gakkai Zasshi|June 21, 2014
[Development of molecular targeted therapies in lung cancers]Kenichi Suda, Tetsuya Mitsudomi
Nature Reviews. Clinical Oncology|February 27, 2013
Surgery for NSCLC in the era of personalized medicineTetsuya Mitsudomi, Kenichi Suda, Yasushi Yatabe
Cancer Science|January 8, 2022
Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancerTakamasa Koga, Kenichi Suda, Tetsuya Mitsudomi
Lung Cancer (Auckland, N.Z.)|July 23, 2021
Lung Cancer with <i>MET</i> exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future ChallengesToshio Fujino, Kenichi Suda, Tetsuya Mitsudomi
Cancer Metastasis Reviews|January 29, 2010
Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutationKenichi Suda, Kenji Tomizawa, Tetsuya Mitsudomi
Cells|February 12, 2021
Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers-Applications and LimitationsShuta Ohara, Kenichi Suda, Tetsuya Mitsudomi
Expert Opinion on Emerging Drugs|July 4, 2020
Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancerToshio Fujino, Kenichi Suda, Tetsuya Mitsudomi
Cells|September 13, 2025
Utility and Future Perspectives of Circulating Tumor DNA Analysis in Non-Small Cell Lung Cancer Patients in the Era of Perioperative Chemo-ImmunotherapyShuta Ohara, Kenichi Suda, Yasuhiro Tsutani
Biomolecules|September 28, 2023
Recent Advances in Perioperative Immunotherapies in Lung CancerShota Fukuda, Kenichi Suda, Akira Hamada, et al.
International Journal of Clinical Oncology|June 10, 2011
Lung cancers unrelated to smoking: characterized by single oncogene addiction?Kenichi Suda, Kenji Tomizawa, Yasushi Yatabe, et al.
Pageof 13

Showing results (11-20 of 127) with videos related to

Sort By:
Pageof 13
Nihon Geka Gakkai Zasshi|June 21, 2014
[Development of molecular targeted therapies in lung cancers]Kenichi Suda, Tetsuya Mitsudomi
Nature Reviews. Clinical Oncology|February 27, 2013
Surgery for NSCLC in the era of personalized medicineTetsuya Mitsudomi, Kenichi Suda, Yasushi Yatabe
Cancer Science|January 8, 2022
Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancerTakamasa Koga, Kenichi Suda, Tetsuya Mitsudomi
Lung Cancer (Auckland, N.Z.)|July 23, 2021
Lung Cancer with <i>MET</i> exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future ChallengesToshio Fujino, Kenichi Suda, Tetsuya Mitsudomi
Cancer Metastasis Reviews|January 29, 2010
Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutationKenichi Suda, Kenji Tomizawa, Tetsuya Mitsudomi
Cells|February 12, 2021
Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers-Applications and LimitationsShuta Ohara, Kenichi Suda, Tetsuya Mitsudomi
Expert Opinion on Emerging Drugs|July 4, 2020
Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancerToshio Fujino, Kenichi Suda, Tetsuya Mitsudomi
Cells|September 13, 2025
Utility and Future Perspectives of Circulating Tumor DNA Analysis in Non-Small Cell Lung Cancer Patients in the Era of Perioperative Chemo-ImmunotherapyShuta Ohara, Kenichi Suda, Yasuhiro Tsutani
Biomolecules|September 28, 2023
Recent Advances in Perioperative Immunotherapies in Lung CancerShota Fukuda, Kenichi Suda, Akira Hamada, et al.
International Journal of Clinical Oncology|June 10, 2011
Lung cancers unrelated to smoking: characterized by single oncogene addiction?Kenichi Suda, Kenji Tomizawa, Yasushi Yatabe, et al.
Pageof 13